Company Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C).
Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 883 |
| CEO | Mark Goldsmith |
Contact Details
Address: 700 Saginaw Drive Redwood City, California 94063 United States | |
| Phone | 650 481 6801 |
| Website | revmed.com |
Stock Details
| Ticker Symbol | RVMDW |
| Exchange | NASDAQ |
| Stock Type | Warrants |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001628171 |
| CUSIP Number | 76155X100 |
| ISIN Number | US76155X1182 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark A. Goldsmith M.D., Ph.D. | Chief Executive Officer, President and Chairman |
| Jack Anders | Chief Financial Officer |
| Margaret A. Horn J.D. | Chief Operating Officer |
| Jeffrey Cislini J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | President of Research and Development |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder and Member of Scientific Advisory Board |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder and Member of Scientific Advisory Board |
| Walter Reiher Ph.D. | Chief Information Officer |
| Jan Smith Ph.D. | Chief Scientific Officer |